Showing 7971-7980 of 8696 results for "".
- "Phenomenal Gains" in Derm Device Market, Global Market Insights Predictshttps://practicaldermatology.com/news/phenomenal-gains-in-derm-device-market-global-market-insights-predicts/2457645/Dermatology devices market, an integral vertical of medical equipment space, of late, has been providing lucrative opportunities to the investors to exploit economies of scale. The claim is very well validated from the increasing attempts by the market giants to brainstorm innovative products tha
- Special to Practical Dermatology: ACS Chief Medical Officer Sounds Off On Sunscreen Misusehttps://practicaldermatology.com/news/special-to-practical-dermatology-acs-chief-medical-officer-sounds-off-on-sunscreen-misuse/2457647/We are getting it all wrong when it comes to our reliance on sunscreen as the be all and end all protection from skin cancer, says Otis W. Brawley, MD, chief medical and scientific officer for the American Cancer Society in Atlanta. Sunscreen wasn’t developed so we could all get a f
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Frequent BCC Linked to Other Cancershttps://practicaldermatology.com/news/frequent-bcc-linked-to-other-cancers/2457651/Basal cell carcinoma may increase risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine. "We discovered that people who develop six or more basal ce
- FDA Committee Recommends Approval of Paratek's Omadacyclinehttps://practicaldermatology.com/news/fda-committee-recommends-approval-of-parateks-omadacycline/2457656/The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4). Paratek Pharmaceuticals,
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an
- FDA Approves Poteligeo for Cutaneous T-Cell Lymphomashttps://practicaldermatology.com/news/fda-approves-poteligeo-for-cutaneous-t-cell-lymphomas/2457657/The FDA approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with two types of cutaneous T-cell lymphoma (CTCL)—relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This a
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Ta
- IRB Approval Means BioPharmX To Move Ahead on Phase 2 Trial of BPX-04 for Rosaceahttps://practicaldermatology.com/news/irb-approval-means-biopharmx-to-move-ahead-on-phase-2-trial-of-bpx-04-for-rosacea/2457665/BioPharmX Corporation has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular rosacea. Based on data from its open-label feasibility study which assessed tolera